Jim Heller, chair of Cozen O'Connor's Products Liability practice, discusses the impact of the Philadelephia pelvic mesh verdict on Johnson & Johnson in Law360. After two consecutive jury verdicts exceeding $12 million, Johnson & Johnson may think seriously about settling roughly 150 cases remaining in the jurisdiction’s mass tort program and focusing on the much larger federal multi-district litigation. To turn the course of the litigation in its favor, J&J is likely looking for one of two developments in its appeals of both Philadelphia verdicts, according to Jim. The first would be a defense verdict that gives it more leverage in any negotiations. The second would be a decision — ideally from an appellate court — that some of the evidence presented by the plaintiffs was inadmissible. 

To read the article, click here.